Abstract
At JADPRO Live 2025, Kevin Y. Chen, PharmD, MS, BCOP, CPP, reviewed therapeutic advances in solid tumors with an emphasis on newly approved targeted therapies and antibody–drug conjugates (ADCs). The session underscored the expanding role of biomarker-driven treatment selection and comprehensive molecular profiling. Dr. Chen also emphasized the role of oncology advanced practitioners in monitoring patients and managing toxicities of these agents in order to optimize outcomes.
